The high-stakes game continues. Like the smaller player in a lively pre-Valentine’s Day tennis match, ImClone Systems Inc. lobbed the ball back into Bristol-Myers Squibb Co.’s court early Tuesday, responding with a polite “no, thanks” to the pharmaceutical giant’s demand to change the terms of their deal regarding FDA-stalled Erbitux (cetuximab) for colorectal cancer. (BioWorld Today) Read More
